Phase 1/2 Study of PX-866 and Cetuximab (Oncothyreon, Inc. PX-866-003)
Phase of Trial: Phase I/II
Latest Information Update: 23 Jun 2016
At a glance
- Drugs Sonolisib (Primary) ; Cetuximab
- Indications Colorectal cancer; Head and neck cancer
- Focus Therapeutic Use
- Sponsors Oncothyreon
- 18 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2013 85 and 83 patients have been enrolled in the colorectal cancer and head and neck cancer groups, with primary efficacy data expected later this month and by year end respectively, according to the Q1 2013 financial report for Oncothyreon.
- 13 May 2013 Planned End Date changed from 1 Apr 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.